Immunovant (IMVT) Payables (2018 - 2026)
Immunovant's (IMVT) quarterly Payables came in at $7.5 million in Q1 2026, down 57.29% YoY from $17.7 million in Q1 2025, and down 12.48% on a QoQ basis from $8.6 million in Q4 2025.
Immunovant (IMVT) Payables (2018 - 2026) Analysis & Trends
Immunovant (IMVT) has 9 years of Payables data on file, last reported at $7.5 million in Q1 2026.
- Quarterly Payables fell 57.29% year-over-year to $7.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.5 million (down 57.29% YoY) and the FY2026 annual result came in at $7.5 million, down 57.29% from the prior year.
- Payables retreated to $7.5 million in Q1 2026, from $8.6 million in the prior quarter.
- In the past five years, Payables ranged from a high of $26.5 million in Q2 2023 to a low of $1.1 million in Q2 2022.
- A 5-year average of $11.0 million and a median of $7.8 million in 2025 frame the typical range for Payables.
- The widest YoY moves for Payables: up 2382.08% in 2023, down 92.74% in 2023.
- Tracing IMVT's Payables over 5 years: stood at $14.0 million in 2022, then plunged by 72.08% to $3.9 million in 2023, then surged by 406.8% to $19.8 million in 2024, then sank by 56.52% to $8.6 million in 2025, then decreased by 12.48% to $7.5 million in 2026.
- The last three Payables figures came in at $7.5 million (Q1 2026), $8.6 million (Q4 2025), and $6.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - | 10.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.14 Mn |
| Mar 31, 2026 | 7.54 Mn |
| Dec 31, 2025 | 8.62 Mn |
| Sep 30, 2025 | 6.92 Mn |
| Jun 30, 2025 | 7.84 Mn |
| Mar 31, 2025 | 17.66 Mn |
| Dec 31, 2024 | 19.82 Mn |
| Sep 30, 2024 | 20.73 Mn |
| Jun 30, 2024 | 11.04 Mn |
| Mar 31, 2024 | 7.16 Mn |
| Dec 31, 2023 | 3.91 Mn |
| Sep 30, 2023 | 7.51 Mn |
| Jun 30, 2023 | 26.46 Mn |
| Mar 31, 2023 | 1.35 Mn |
| Dec 31, 2022 | 14.00 Mn |
| Sep 30, 2022 | 7.46 Mn |
| Jun 30, 2022 | 1.07 Mn |
| Mar 31, 2022 | 18.63 Mn |
| Dec 31, 2021 | 3.83 Mn |
| Sep 30, 2021 | 4.24 Mn |